A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent Temozolomide Resistant Glioblastoma: An NRG Oncology RTOG Group Study

This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was tested using 2 randomized schedules (5 versus 21 days), w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Robins, H Ian, Zhang, Peixin, Gilbert, Mark R, Chakravarti, Arnab, de Groot, John F, Grimm, Sean A, Wang, Fen, Lieberman, Frank S, Krauze, Andra, Trotti, Andy M, Mohile, Nimish, Kee, Andrew Y J, Colman, Howard, Cavaliere, Robert, Kesari, Santosh, Chmura, Steven J, Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4720526/
https://ncbi.nlm.nih.gov/pubmed/26508094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1966-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados